Microbiology and Biotechnology Letters (한국미생물·생명공학회지)

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Synergistic Anticancer Activity of a Mixture of Anticancer Agent with Proteoglycan from Rhanella aquatilis against Human Colon Cancer Cell HT29

Rhanella aquatilis 유래 당단백질과 항암제 혼합물에 의한 인체 대장암 HT29세포에 대한 항암상승효과

  • Park, Hae-Ji (Department of Life Science and Biotechnology, Dong-Eui University) ;
  • Kim, Kwang-Hyeon (Department of Life Science and Biotechnology, Dong-Eui University)
  • 박혜지 (동의대학교 자연대 생명응용학과) ;
  • 김광현 (동의대학교 자연대 생명응용학과)
  • Received : 2013.05.09
  • Accepted : 2013.06.04
  • Published : 2013.09.28
Download PDF
⟨ Previous Next ⟩

Abstract

In order to investigate the anticancer activity of an anti-yeast substance (AYS), a proteoglycan produced by Rhanella aquatilis AY2000, the cytotoxicity of the AYS against cancer cells was determined in vitro. The AYS was not cytotoxic to the human Jurkat T cell or the mouse sarcoma 180 cell, but was cytotoxic to the human colon cancer TH20 cell. The AYS was increasingly cytotoxic against human colon cancer cells in a dose-dependent manner at range from 62.5 to 500 ${\mu}g/ml$. Anticancer activity by combination of the AYS and an anticancer agent was also determined. The anticancer agent combined with the AYS was shown to possess greater synergistic anticancer activity against human colon cancer cells, as compared with the anticancer agent alone.

Rhanella aquatilis AY2000 균주가 생산하는 일종의 당단백질인 항효모성 물질 (AYS)에 대한 항암활성을 조사하기 위해 in vitro에서 암세포에 대한 AYS의 세포독성을 조사하였다. 그 결과 AYS는 인체의 Jurkat T 세포와 마우스의 sarcoma 180 세포에 대해서는 세포독성을 나타내지 않았으나, 인체 대장암세포인 colon cancer TH20 세포에는 세포독성을 나타내었다. 또한 이 AYS는 62.5에서 500 ${\mu}g/ml$까지 농도의존적으로 인체대장암세포에 대해 세포독성을 증가시켰다. 뿐만 아니라 이 AYS와 시판 항암제를 혼합하여 처리한 결과 시판 항암제를 단독으로 처리한 것 보다 인체대장암세포에 대한 항암효과가 더욱 상승되었다.

Keywords

References

  1. Abe T, Hasegawa S, Taniguchi K, Yokomizo A, Kuwano T, Ono M, et al. 1994. Possible involvement of multi-drug-resistance- associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells. Int. J. Cancer. 58: 860-864. https://doi.org/10.1002/ijc.2910580619
  2. Ahn JB, Shim KY, Jeung HC, Rha SY, Yoo NC, Kim NK, et al. 2001. Monthly 5-days 5-Fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer. Cancer Lett. 167: 215-224. https://doi.org/10.1016/S0304-3835(01)00485-2
  3. Beggs WH. 1993. Anti-Candida activity of the anti-cancer drug tamoxifen. Res. Commun. Chem. Pathol. Pharmacol. 80: 125-128.
  4. Canfield CJ, Pudney M, Gutteridge WE. 1995. Interaction of Atovaquone with other antimalarial drugs against Plasmodium flaciparum in vitro. Exp. Parasitol. 80: 373-381. https://doi.org/10.1006/expr.1995.1049
  5. Ciapetti G, Cenni E, Pratelli L, Pizzoferrato A. 1993. In vitro valuation of cell/biomaterial interaction by MTT assay. Biomaterials. 14: 359-364. https://doi.org/10.1016/0142-9612(93)90055-7
  6. Irving T. 2008. Current perspective adjuvant chemotheraphy after resection of liver metastases from colorectal cancer. Eur. J. Cancer. 44: 1198-1201. https://doi.org/10.1016/j.ejca.2008.04.007
  7. Jekunen AP, Christen RD, Shalinsky DR. 1994. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br. J. Cancer. 69: 299-306. https://doi.org/10.1038/bjc.1994.55
  8. Langer CJ, Leighton JC, Comis RL. 1995. Paclitaxel and carboplatin in combination in the treatment of advanced nonsmall cell lung cancer: a phase II toxicity, response, and survival analysis. J. Clin. Oncol. 13: 1860-1870.
  9. Lee M, Yea SS, Jeon YJ. 2000. Paclitaxel causes mouse splenic lymphocytes to a state hyporesponsive to lipopolysaccharide stimulation. Int. J. Immunopharmacol. 22: 615-621. https://doi.org/10.1016/S0192-0561(00)00024-2
  10. Longhi A, Mariani E, Kuehn JJ. 2009. A randomized study with adjuvant mistletoe versus oral Etoposide on post relapse disease-free survival in osteosarcoma patients. Eur. J. Integrative Med. 1: 27-33. https://doi.org/10.1016/j.eujim.2009.02.005
  11. McClendon AK, Osheroff N, 2007. DNA topoisomerase II, genotoxicity, and cancer. Mutat. Res. 623: 83-97. https://doi.org/10.1016/j.mrfmmm.2007.06.009
  12. Mihich E, Ehrke MJ. 2000. Anticancer drugs plus cytokines: immunomodulation based therapies of mouse tumors. Int. J. Immunopharmacol. 22: 1077-1081. https://doi.org/10.1016/S0192-0561(00)00072-2
  13. Park BT, Na KH, Jung EC, Park JW, Kim HH. 2009. Antifungal and anticancer activities of a protein from the mushroom Cordyceps militaris. Korean J. Physiol. Pharmacol. 13: 49-54. https://doi.org/10.4196/kjpp.2009.13.1.49
  14. Papoian T, Lewis W. 1990. Adriamycin cardiotoxicity in vivo, Selective alterations in rat cardiac mRNAs. Am. J. Pathol. 130: 1201-1207.
  15. Park HJ, Kang MJ, Lee JH, Kim KH. 2011. Action pattern of anti- yeast substance originated from Rahnella aquatilis strain AY2000. Korean J. Microbiol. 47: 163-166.
  16. Shinoda C, Fujishita MM, Dohkan J, Oda H, Shinoda K, Yamada T, et al. 2005. Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung lines by the c-jun N-terminal kinase pathway. Int. J. Cancer. 117: 21-31. https://doi.org/10.1002/ijc.21094
  17. Suehisa H, Toyooka S. 2009. Adjuvant chemotheraphy for completely resected non-small-cell lung cancer. Acta Med. Okayama. 63: 223-230.
  18. Wang ZH, Wu BJ, Zhang XH, Xu M, Chang HM, Lu XY, et al. 2012. Purification of a polysaccharide from Boschniakia rossica and its synergistic antitumor effect combined with 5-fluorouracil. Carbohydr. Polym. 89: 31-35. https://doi.org/10.1016/j.carbpol.2012.02.024
  19. Zhou H, Shen T, Luo Y, Liu L, Chen W, Xu B, et al. 2010. The antitumor activity of the fungicide ciclopirox. Int. J. Cancer. 127: 2467-2477. https://doi.org/10.1002/ijc.25255